Description
Hybridoma technology is a standard method for antibody development. By fusion of antibody-producing B-cells with myeloma cells, an immortalized hybrid cell line is generated that produces large quantities of one specific monoclonal antibody directed against your antigen of interest.
InVivo offers custom services for mouse hybridoma development. Depending on your specific needs, we provide flexible and customized solutions to develop high-affinity antibodies against your antigen of interest. The entire process, including immunization, cell fusion, screening, cloning and initial characterization usually takes around 4-5 months.
This service includes: - Development of murine monoclonal antibodies against haptens, peptides, and protein
- For research and IVD kit manufacturing
Extras: - Screening of antibody pairs for sandwich-ELISA
- Negative-screening to avoid cross-reactions of antibodies
- Isotyping
- Mycoplasma testing
- Cryopreservation of clones
- Small-scale test production of monoclonal antibodies from hybridoma